Revised Result for FY 31/03/2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Caprolactam Chemicals has submitted revised audited financial results for FY25, citing minor clerical errors in the original filing. Revenue from operations fell to ₹673.96 lakhs from ₹695.73 lakhs in FY24, a decline of about 3%. The company swung to a loss after tax of ₹70.87 lakhs in FY25, compared to a profit of ₹19.74 lakhs in FY24. On the balance sheet, short-term borrowings jumped sharply to ₹871.34 lakhs (from ₹586.27 lakhs), while other equity eroded to just ₹22.85 lakhs. Cash flow from operations turned deeply negative at ₹(214.33) lakhs, a major worsening from ₹(44.48) lakhs last year. The auditor (Pulindra Patel & Co.) issued an unqualified opinion with no qualifications or emphasis of matter.
Negative for shareholders — the company slipped into a loss, revenue shrank, short-term debt surged close to twice the equity base, and operating cash burn worsened sharply, signalling serious financial stress despite the clean auditor opinion.